Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD
Shot:
- Santhera has discontinued the development of Puldysa (idebenone) in patients with DMD who are in respiratory decline and receive concomitant glucocorticoid treatment. The DSMB has recommended the discontinuation of the SIDEROS study due to futility as it fails to meet its 1EPs i.e. the change of FVC%p from baseline to 18mos. of treatment
- Following the discontinuation- the company intends to initiate a restructuring plan- focusing on Vamorolone for DMD- lonodelestat for cystic fibrosis and other lung diseases- and its discovery-stage gene therapy approach for congenital muscular dystrophy
- Additionally- Santhera will withdraw the EU’s MAA and end the global development program for Puldysa. Participants who are enrolled in the study will discontinue study medication and complete the study’s follow-up evaluations
Ref: Santhera | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com